Cell Mosaic

CellMosaic is a private, revenue-generating biotechnology company that operates as a specialized platform and service provider in the bioconjugation space. Founded in 2008, the company leverages its proprietary AqueaTether® (AqT®) technology to offer a comprehensive portfolio of kits, reagents, and custom development services for creating next-generation bioconjugates, primarily serving the research, diagnostic, and therapeutic development markets. Its business model combines direct product sales through an online store with fee-for-service custom bioconjugation, ADC development, and analytical support. While not developing its own therapeutics, CellMosaic is a critical enabler for companies advancing targeted therapies like ADCs, peptide-drug conjugates (PDCs), and other complex bioconjugates.

Proprietary AqueaTether® (AqT®) technology for stable, homogeneous bioconjugation; specialized crosslinkers (sxLink™, oxLink™); and a suite of analytical and purification methods for bioconjugate development.

CellMosaic competes in a fragmented landscape that includes large life science reagent companies (e.g., Thermo Fisher), specialty conjugation service providers, and large CDMOs with bioconjugation capabilities. Its differentiation hinges on its proprietary AqT® technology, which aims to solve specific stability and homogeneity challenges in conjugate synthesis.